Prospects of using the genetically engineered preparation dupilumab for the treatment of atopic dermatitis in the adult population

Abstract

Background  Currently, the genetically engineered drug dupilumab, which was recently registered in Russia and is planned for use, is widely used in the world for the treatment of atopic dermatitis..   Objective Possibility of use of the genetically engineered drug dupilumab for the treatment of atopic dermatitis among adult population.   Methods To address the issues of treatment tactics in patients with atopic dermatitis, a 12-week placebo-controlled study of its effectiveness was carried out on two control groups of 45 people each, divided into three subgroups of 15 people (1 subgroup - placebo; subgroup 2 - dupilumab 300 mg subcutaneously 1 time in 2 weeks; subgroup 3 - dupilumab 200 mg subcutaneously 1 time per week). Evaluation of the effectiveness of the treatment of atopic dermatitis with the targeted drug dupilumab was carried out using the following scales: EASI, IGA, NRS, SCORAD, POEM, DLQI, HADS.   Results The results of the study show a significant improvement in the symptoms and manifestations of atopic dermatitis according to the SCORAD, EASI-70 and POEM scales. All patients taking dupilumab showed cleansing of the skin, a decrease in the intensity of pain and skin itching, which contributes to an improvement in the quality of life of patients with atopic dermatitis (a decrease in the DLQI value from 12-14 to 6-7), as well as a decrease in the level of anxiety and stress. At the same time, the number of side effects that occur in patients taking dupilumab and placebo is comparable.   Conclusion Based on the study and the results of earlier studies of the effectiveness of targeted therapy of atopic dermatitis with the genetically engineered drug dupilumab, it is possible to recommend a regimen for the use of this drug registered in the Russian Federation for the treatment of atopic dermatitis in the adult population: the initial dose of the drug is 600 mg, then 300 mg every 2 weeks with the regular use of moisturizers 2 times a day during the entire period of treatment. In the case of a protracted severe course of the disease, a weekly subcutaneous injection of the drug at a dose of 200-300 mg is possible.   Key words Atopic dermatitis, targeted therapy, genetically engineered drugs, dupilumab.